Cabotegravir and rilpivirine are antiretroviral medicines used together as a long acting treatment option for certain adults living with HIV. Unlike traditional daily oral HIV medicines, this treatment may be administered as scheduled injections after appropriate medical evaluation. Understanding how the medicines work, who may be eligible, and why regular appointments are important can help patients discuss treatment options with healthcare professionals. This article provides general educational information about cabotegravir and rilpivirine, their role in HIV treatment, dosing considerations, possible benefits, side effects, and the importance of ongoing viral load monitoring.
Cabotegravir and rilpivirine are used together as a complete antiretroviral treatment regimen for certain people with HIV. Cabotegravir is an integrase strand transfer inhibitor, while rilpivirine is a non nucleoside reverse transcriptase inhibitor. The combination works by targeting different stages of the HIV replication process. For eligible individuals whose HIV is already well controlled, a long acting injectable regimen may provide an alternative to taking oral HIV medication every day. Treatment decisions should be based on medical history, laboratory results, possible drug interactions, and guidance from a qualified healthcare professional.
HIV treatment involves using antiretroviral medicines to reduce the amount of HIV in the body. When treatment is effective and taken as prescribed, the viral load can become suppressed. Cabotegravir and rilpivirine work through different mechanisms, helping prevent HIV from making additional copies of itself.
Before starting this treatment, healthcare professionals generally evaluate whether the regimen is appropriate for the individual. Factors such as viral suppression, previous treatment history, resistance information, liver health, and other medicines may be considered. Because the injectable medicines remain in the body for an extended period, following the recommended treatment schedule is an important part of maintaining effective drug levels.
Key points about this treatment include:
Long acting cabotegravir and rilpivirine may be considered for people who meet specific clinical requirements. This option can be useful for individuals who prefer scheduled treatment visits instead of taking oral medication every day. However, injectable treatment may not be suitable for everyone, and personal preferences alone are not the only factor considered when selecting an HIV regimen.
Like other medicines, cabotegravir and rilpivirine can cause side effects. Injection site reactions, such as pain, swelling, or discomfort, may occur. Other possible effects can vary between individuals. Healthcare professionals may also review potential interactions with other medicines because some drugs can affect rilpivirine or cabotegravir levels.
Important aspects of ongoing treatment include:
Cabotegravir and rilpivirine represent an additional approach to HIV management for appropriately selected individuals. Understanding treatment requirements, monitoring needs, and the importance of consistent medical follow up can help people have informed discussions with their healthcare professionals. This information is provided for educational purposes only and does not replace individualized medical advice, diagnosis, or treatment.